Evidence map›Paper›PMID 28976791›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

Charles S Fuchs, Donna Niedzwiecki, Harvey J Mamon, Joel E Tepper, Xing Ye, Richard S Swanson, Peter C Enzinger, Daniel G Haller, Tomislav Dragovich, Steven R Alberts and 11 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 8 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 8 syntheses or guidelines pooled it, 134 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Guideline
  4. Pooled it
  5. Pooled it
  6. Adjuvant radiochemotherapy vs. chemotherapy alone in gastric cancer: a meta-analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019
    Pooled it
  7. Pooled it
  8. Guideline
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Adjuvant treatment for locally advanced gastric cancer: an Asian perspective.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Charles S FuchsCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Donna NiedzwieckiCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Harvey J MamonCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Joel E TepperCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Xing YeCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Richard S SwansonCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Peter C EnzingerCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Daniel G HallerCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Tomislav DragovichCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Steven R AlbertsCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Georg A BjarnasonCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Christopher G WillettCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Leonard L GundersonCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Richard M GoldbergCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Alan P VenookCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
David IlsonCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Eileen O'ReillyCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Kristen CiomborCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
David J BergCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Jeffrey MeyerhardtCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Robert J MayerCharles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.
Dana-Farber Brigham Cancer Center · US

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL · 2014 to 2026
$206.8M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
CANCER AND LEUKEMIA GROUP B MINORITY SATELLITE SUPPLEMENU10CA031946 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 1985 to 2013
$158.4M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
CANCER &LEUKEMIA GROUP B STATISTICAL CENTERU10CA033601 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SARGENT, DANIEL J. · 1985 to 2013
$69.4M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2M
Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
OSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8M
NCATS NIH HHS UL1 TR001863NCI NIH HHS K12 CA090625NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA149222NCI NIH HHS R01 CA169141NCI NIH HHS U10 CA031946NCI NIH HHS U10 CA032291NCI NIH HHS U10 CA033601NCI NIH HHS U10 CA047577NCI NIH HHS U10 CA047642NCI NIH HHS U10 CA077651NCI NIH HHS U10 CA077658NCI NIH HHS U10 CA138561NCI NIH HHS U10 CA180790NCI NIH HHS U10 CA180791NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180838NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180857NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180868NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888
6 · The paper itself

Abstract

Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone. CALGB 80101 (Alliance; Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma) assessed whether a postoperative chemoradiotherapy regimen that replaced FU plus LV with a potentially more active systemic therapy could further improve overall survival. Patients and Methods Between April 2002 and May 2009, 546 patients who had undergone a curative resection of stage IB through IV (M0) gastric or gastroesophageal junction adenocarcinoma were randomly assigned to receive either postoperative FU plus LV before and after combined FU and radiotherapy (FU plus LV arm) or postoperative epirubicin, cisplatin, and infusional FU (ECF) before and after combined FU and radiotherapy (ECF arm). Results With a median follow-up duration of 6.5 years, 5-year overall survival rates were 44% in the FU plus LV arm and 44% in the ECF arm ( P

Indexed as

Chemoradiotherapy, AdjuvantEsophagogastric JunctionAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCisplatinCombined Modality TherapyEpirubicinFemaleFluorouracilHumansLeucovorinMaleMiddle AgedCisplatinEpirubicinFluorouracilLeucovorin

Identifiers

PMID28976791
PMCPMC5678342
OpenAlexW2763640718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.